Regorafenib for recurring meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a meningioma (type of brain tumor) that has come back or grown in the last year.
- You are not able to have more surgery or radiation for this tumor.
- You have a tumor sample from a past surgery or biopsy that can be tested.
- You are generally healthy enough for daily activities (ECOG 0 or 1).
- You have not had any other chemotherapy or drug treatment for this meningioma before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
Hear when a new Meningioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.